Back to Search Start Over

Abscopal effect induced by cryoablation in a 55-year-old patient with metastatic dedifferentiated liposarcoma: a case report.

Authors :
Wetterwald L
Papadopoulos S
Tsoumakidou G
Boughdad S
Ferraro D
Koulouris P
Cherix S
Duran R
Digklia A
Source :
Annals of translational medicine [Ann Transl Med] 2024 Oct 20; Vol. 12 (5), pp. 94. Date of Electronic Publication: 2024 Oct 15.
Publication Year :
2024

Abstract

Background: Metastatic dedifferentiated liposarcoma (DDLPS) is primarily managed with chemotherapy, yet with poor response rate. Locoregional therapies, such as radiotherapy and percutaneous cryoablation, can provide palliation for inoperable metastatic sarcomas. In rare instances, those ablative therapies can elicit an immune-mediated regression of untreated metastases in a process named the abscopal effect. With the growing use of immunotherapy, reports on the abscopal effect have become more frequent during the last decade.<br />Case Description: A 55-year-old patient with no prior medical history was diagnosed with a stage IV DDLPS. The patient was first treated with induction chemotherapy followed by en bloc resection and adjuvant radiotherapy. After two local relapses treated with chemotherapy, the patient developed a systemic disease progression. While progressing on immunochemotherapy, the patient underwent palliative percutaneous cryoablation. Three months after the procedure, the <superscript>18</superscript> fluorodeoxyglucose positron emission tomography/computed tomography ( <superscript>18</superscript> FDG PET/CT) showed regression of the distant metastasis alongside the regression of the cryoablated tumor, suggesting an abscopal effect.<br />Conclusions: The occurrence of the abscopal effect after progressive disease suggests that cryoablation triggered a systemic immune response, highlighting the potential of this treatment combination. However, it remains a rare phenomenon, and further research and clinical trials are required to determine optimal treatment sequencing.<br />Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-1868/coif). R.D. reports payment or honoraria via institution by Society of Interventional Oncology, Boston Scientific, Guerbet and BTG. A.D. reports payment or honoraria via the institution by Genentech/Roche, Pharmamar, Traconpharma, AstraZeneca, Boston Scientific and Bristol-Myers Squibb. The other authors have no conflicts of interest to declare.<br /> (2024 AME Publishing Company. All rights reserved.)

Details

Language :
English
ISSN :
2305-5839
Volume :
12
Issue :
5
Database :
MEDLINE
Journal :
Annals of translational medicine
Publication Type :
Academic Journal
Accession number :
39507450
Full Text :
https://doi.org/10.21037/atm-23-1868